162 related articles for article (PubMed ID: 31516385)
1. NAP1L1 is a prognostic biomarker and contribute to doxorubicin chemotherapy resistance in human hepatocellular carcinoma.
Le Y; Kan A; Li QJ; He MK; Chen HL; Shi M
Cancer Cell Int; 2019; 19():228. PubMed ID: 31516385
[TBL] [Abstract][Full Text] [Related]
2. NAP1L1 Functions as a Tumor Promoter
Zhang YW; Chen Q; Li B; Li HY; Zhao XK; Xiao YY; Liu S; Zuo S
Front Cell Dev Biol; 2021; 9():659680. PubMed ID: 34368121
[TBL] [Abstract][Full Text] [Related]
3. NAP1L1 Functions as a Novel Prognostic Biomarker Associated With Macrophages and Promotes Tumor Progression by Influencing the Wnt/β-Catenin Pathway in Hepatocellular Carcinoma.
Shen B; Zhu W; Liu X; Jiang J
Front Genet; 2022; 13():876253. PubMed ID: 35664324
[TBL] [Abstract][Full Text] [Related]
4. A novel prognostic biomarker SPC24 up-regulated in hepatocellular carcinoma.
Zhu P; Jin J; Liao Y; Li J; Yu XZ; Liao W; He S
Oncotarget; 2015 Dec; 6(38):41383-97. PubMed ID: 26515591
[TBL] [Abstract][Full Text] [Related]
5. NAP1L1 regulates BIRC2 ubiquitination modification via E3 ubiquitin ligase UBR4 and hence determines hepatocellular carcinoma progression.
Zhang SL; Zhang SJ; Li L; Zhang YW; Wang Z; Wang L; Lu JY; Chen TX; Zuo S
Cell Death Discov; 2024 Mar; 10(1):154. PubMed ID: 38538582
[TBL] [Abstract][Full Text] [Related]
6. NAP1L1 promotes proliferation and chemoresistance in glioma by inducing CCND1/CDK4/CDK6 expression through its interaction with HDGF and activation of c-Jun.
Chen Z; Xie Y; Luo H; Song Y; Que T; Hu R; Huang H; Luo K; Li C; Qin C; Zheng C; Fang W; Liu L; Long H; Luo Q
Aging (Albany NY); 2021 Dec; 13(24):26180-26200. PubMed ID: 34959221
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of Protein Phosphatase 1γ (PP1γ) Is Associated with Enhanced Cell Proliferation and Poor Prognosis in Hepatocellular Carcinoma.
Li C; Wu M; Zong G; Wan C; Liu Q; Zhou H; Hua L; Chen Y; Chen X; Lu C
Dig Dis Sci; 2017 Jan; 62(1):133-142. PubMed ID: 27921263
[TBL] [Abstract][Full Text] [Related]
8. NAP1L1 promotes tumor proliferation through HDGF/C-JUN signaling in ovarian cancer.
Xiaohua Zhu ; Xie Y; Huang W; Chen Z; Guo S
BMC Cancer; 2022 Mar; 22(1):339. PubMed ID: 35351053
[TBL] [Abstract][Full Text] [Related]
9. LINC00680 enhances hepatocellular carcinoma stemness behavior and chemoresistance by sponging miR-568 to upregulate AKT3.
Shu G; Su H; Wang Z; Lai S; Wang Y; Liu X; Dai L; Bi Y; Chen W; Huang W; Zhou Z; He S; Dai H; Tang B
J Exp Clin Cancer Res; 2021 Jan; 40(1):45. PubMed ID: 33499874
[TBL] [Abstract][Full Text] [Related]
10. Nucleosome assembly protein 1-like 1 (NAP1L1) in gastric cancer patients: a potential biomarker with diagnostic and prognostic utility.
Gul G; Aydin MA; Algul S; Kiziltan R; Kemik O
Biomarkers; 2024 Feb; 29(1):30-35. PubMed ID: 38258494
[TBL] [Abstract][Full Text] [Related]
11. IFI44L is a novel tumor suppressor in human hepatocellular carcinoma affecting cancer stemness, metastasis, and drug resistance via regulating met/Src signaling pathway.
Huang WC; Tung SL; Chen YL; Chen PM; Chu PY
BMC Cancer; 2018 May; 18(1):609. PubMed ID: 29848298
[TBL] [Abstract][Full Text] [Related]
12. Upregulation of Stress-Induced Protein Kinase CK1 Delta is associated with a Poor Prognosis for patients with Hepatocellular Carcinoma.
Zhang H; Qiu C; Zeng H; Zhu W; Lyu W; Lao X
Genet Test Mol Biomarkers; 2021 Jul; 25(7):504-514. PubMed ID: 34280005
[No Abstract] [Full Text] [Related]
13. Neuron-glial antigen 2 overexpression in hepatocellular carcinoma predicts poor prognosis.
Lu LL; Sun J; Lai JJ; Jiang Y; Bai LH; Zhang LD
World J Gastroenterol; 2015 Jun; 21(21):6649-59. PubMed ID: 26074703
[TBL] [Abstract][Full Text] [Related]
14. High expression of transcriptional coactivator p300 correlates with aggressive features and poor prognosis of hepatocellular carcinoma.
Li M; Luo RZ; Chen JW; Cao Y; Lu JB; He JH; Wu QL; Cai MY
J Transl Med; 2011 Jan; 9():5. PubMed ID: 21205329
[TBL] [Abstract][Full Text] [Related]
15. NAP1L1: A Novel Human Colorectal Cancer Biomarker Derived From Animal Models of
Queiroz CJS; Song F; Reed KR; Al-Khafaji N; Clarke AR; Vimalachandran D; Miyajima F; Pritchard DM; Jenkins JR
Front Oncol; 2020; 10():1565. PubMed ID: 32850460
[TBL] [Abstract][Full Text] [Related]
16. MCM6 promotes metastasis of hepatocellular carcinoma via MEK/ERK pathway and serves as a novel serum biomarker for early recurrence.
Liu M; Hu Q; Tu M; Wang X; Yang Z; Yang G; Luo R
J Exp Clin Cancer Res; 2018 Jan; 37(1):10. PubMed ID: 29357919
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of NAP1L1 expression in patients with early lung adenocarcinoma.
Nagashio R; Kuchitsu Y; Igawa S; Kusuhara S; Naoki K; Satoh Y; Ichinoe M; Murakumo Y; Saegusa M; Sato Y
Biomed Res; 2020; 41(3):149-159. PubMed ID: 32522932
[TBL] [Abstract][Full Text] [Related]
18. Low expression of organic anion-transporting polypeptide 1B3 predicts a poor prognosis in hepatocellular carcinoma.
Chen S; Li K; Jiang J; Wang X; Chai Y; Zhang C; Deng Q; Shuai L; Feng K; Ma K; Zhang L
World J Surg Oncol; 2020 Jun; 18(1):127. PubMed ID: 32534581
[TBL] [Abstract][Full Text] [Related]
19. Integrator complex subunit 6 (INTS6) inhibits hepatocellular carcinoma growth by Wnt pathway and serve as a prognostic marker.
Lui KY; Zhao H; Qiu C; Li C; Zhang Z; Peng H; Fu R; Chen HA; Lu MQ
BMC Cancer; 2017 Sep; 17(1):644. PubMed ID: 28899352
[TBL] [Abstract][Full Text] [Related]
20. Hepatocellular Carcinoma and Nuclear Paraspeckles: Induction in Chemoresistance and Prediction for Poor Survival.
Kessler SM; Hosseini K; Hussein UK; Kim KM; List M; Schultheiß CS; Schulz MH; Laggai S; Jang KY; Kiemer AK
Cell Physiol Biochem; 2019; 52(4):787-801. PubMed ID: 30946555
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
